BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

BioMarin Pharmaceutical Inc.

Biomarin Pharmaceutical Inc. ($BMRN) announced an update on their ongoing clinical study. BioMarin (BMRN) has launched IMPALA, a Phase 4 study titl...

BioMarin’s IMPALA Study Aims to Boost Palynziq Value With Better Tolerability

BioMarin Pharmaceutical ( ($BMRN) ) has issued an announcement. On June 2, 2026, BioMarin Pharmaceutical Inc. held its 2026 Annual Meeting of Stock...

BioMarin Shareholders Approve 2026 Governance and Equity Plan

In a report released today, from Guggenheim maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $86.00. In addition to Gugge...

BioMarin Pharmaceutical (BMRN) Receives a Buy from Guggenheim

With markets calming after a busy earnings season, analysts say three stocks stand out this week: Futu Holdings ($FUTU), Intuit ($INTU), and BioMar...

3 Best Stocks to Buy This Week, According to Analysts – May 25-May 29

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Hold rating on BioMarin Pharmaceutical, with a price target of $68.00. M...

BioMarin Pharmaceutical (BMRN) Receives a Hold from Stifel Nicolaus

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN), Twist Bioscience (TW...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on BioMarin Pharmaceutical today and set a price target of $68.00. Matteis covers the...

BioMarin Pharmaceutical (BMRN) Gets a Hold from Stifel Nicolaus

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vaxcyte (PCVX) and BioMarin Pharmaceutical (BMRN) wi...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BMRN	$54.69	-0.60%	3.48M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BMRN	$54.69	-0.6%	3.48M
3
4
5
6

BMRN

BMRN

Get BioMarin Pharmaceutical Inc. Data in Excel

Get BioMarin Pharmaceutical Inc. Data in Excel